Response to: Atezolizumab plus bevacizumab in unresectable HCC: insights from the AMETHISTA trial interim analysis

L Rimassa1, C Astolfi2, F Piscaglia3

  • 1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

ESMO Open
|April 1, 2025
PubMed
Abstract

No abstract available in PubMed .